Immunoregulatory cyclophilin a improves low-dose chemotherapy with a modulation of the immune tumor microenvironment in experimental models of melanoma B16 and lymphoma EL4 in vivo-Reference-Cited by-同舟云学术

Immunoregulatory cyclophilin a improves low-dose chemotherapy with a modulation of the immune tumor microenvironment in experimental models of melanoma B16 and lymphoma EL4 in vivo

Published:2024-06-24 Issue: Volume: Page:
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kalinina Anastasiia A.,Tilova Leila R.,Kazansky Dmitry B.,Khromykh Ludmila M.

Funder

Russian Science Foundation

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00280-024-04691-3.pdf

Reference41 articles.

1. Wu J, Waxman DJ (2018) Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett 419:210–222. https://doi.org/10.1016/j.canlet.2018.01.050

2. Schirrmacher V (2019) From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (review). Int J Oncol 54(2):407–419. https://doi.org/10.3892/ijo.2018.4661

3. Xie X, Wu Y, Luo S, Yang H, Li L, Zhou S et al (2017) Efficacy and toxicity of low-dose versus conventional-dose chemotherapy for malignant tumors: a Meta-analysis of 6 randomized controlled trials. Asian Pac J Cancer Prev 18(2):479–484. https://doi.org/10.22034/APJCP.2017.18.2.479

4. Shurin MR, Naiditch H, Gutkin DW, Umansky V, Shurin GV (2012) ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. Curr Med Chem 19(12):1792–1803. https://doi.org/10.2174/092986712800099785

5. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I et al (2015) Trial Watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology 4(4):e1008866. https://doi.org/10.1080/2162402X.2015.1008866